{
  "study_id": "CALGB 40503",
  "study_title": "Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptorâ€“Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)",
  "table_name": "Table 1",
  "table_title": "Patient Demographic and Tumor Characteristics",
  "footnotes": [
    "Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor."
  ],
  "groups": [
    {
      "name": "Letrozole + Bevacizumab",
      "n": 173,
      "type": "Intervention"
    },
    {
      "name": "Letrozole",
      "n": 170,
      "type": "Intervention"
    }
  ],
  "characteristics": [
    {
      "original_label": "Disease measurability",
      "standardized_name": "Disease Measurability",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Measurable",
      "standardized_name": "Measurable Disease",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Measurability",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 67.0,
          "percentage": 39.0,
          "raw_string": "67 39"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 63.0,
          "percentage": 37.0,
          "raw_string": "63 37"
        }
      ]
    },
    {
      "original_label": "Bone only",
      "standardized_name": "Bone-only Disease",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease Measurability",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 106.0,
          "percentage": 61.0,
          "raw_string": "106 61"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 107.0,
          "percentage": 63.0,
          "raw_string": "107 63"
        }
      ]
    },
    {
      "original_label": "Race",
      "standardized_name": "Race",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "White",
      "standardized_name": "Race",
      "category": "White",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 154.0,
          "percentage": 89.0,
          "raw_string": "154 89"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 155.0,
          "percentage": 91.0,
          "raw_string": "155 91"
        }
      ]
    },
    {
      "original_label": "Black",
      "standardized_name": "Race",
      "category": "Black",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.0,
          "raw_string": "2 1"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 2"
        }
      ]
    },
    {
      "original_label": "Asian",
      "standardized_name": "Race",
      "category": "Asian",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.0,
          "raw_string": "2 1"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 0"
        }
      ]
    },
    {
      "original_label": "All other, including multiracial",
      "standardized_name": "Race",
      "category": "Other or multiracial",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Race",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 5.0,
          "raw_string": "8 5"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 5.0,
          "raw_string": "8 5"
        }
      ]
    },
    {
      "original_label": "Age, years",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Median (Range)",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "numeric_median_iqr",
          "median": 56.0,
          "iqr_min": 25.0,
          "iqr_max": 89.0,
          "raw_string": "56 (25-89)"
        },
        {
          "group_name": "Letrozole",
          "data_type": "numeric_median_iqr",
          "median": 59.0,
          "iqr_min": 29.0,
          "iqr_max": 87.0,
          "raw_string": "59 (29-87)"
        }
      ]
    },
    {
      "original_label": "Age, years",
      "standardized_name": "Age Group",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "< 30",
      "standardized_name": "Age Group",
      "unit": "years",
      "category": "<30",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age Group",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.0,
          "raw_string": "1 1"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.0,
          "raw_string": "1 1"
        }
      ]
    },
    {
      "original_label": "31-40",
      "standardized_name": "Age Group",
      "unit": "years",
      "category": "31-40",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age Group",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 10.0,
          "raw_string": "17 10"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 13.0,
          "percentage": 8.0,
          "raw_string": "13 8"
        }
      ]
    },
    {
      "original_label": "41-50",
      "standardized_name": "Age Group",
      "unit": "years",
      "category": "41-50",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age Group",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 35.0,
          "percentage": 20.0,
          "raw_string": "35 20"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 15.0,
          "raw_string": "25 15"
        }
      ]
    },
    {
      "original_label": "51-60",
      "standardized_name": "Age Group",
      "unit": "years",
      "category": "51-60",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age Group",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 53.0,
          "percentage": 31.0,
          "raw_string": "53 31"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 54.0,
          "percentage": 32.0,
          "raw_string": "54 32"
        }
      ]
    },
    {
      "original_label": "61-70",
      "standardized_name": "Age Group",
      "unit": "years",
      "category": "61-70",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age Group",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 53.0,
          "percentage": 31.0,
          "raw_string": "53 31"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 59.0,
          "percentage": 35.0,
          "raw_string": "59 35"
        }
      ]
    },
    {
      "original_label": "71-80",
      "standardized_name": "Age Group",
      "unit": "years",
      "category": "71-80",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age Group",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 17.0,
          "percentage": 10.0,
          "raw_string": "17 10"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 8.0,
          "percentage": 5.0,
          "raw_string": "8 5"
        }
      ]
    },
    {
      "original_label": "80+",
      "standardized_name": "Age Group",
      "unit": "years",
      "category": ">=80",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age Group",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.0,
          "raw_string": "5 3"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.0,
          "raw_string": "5 3"
        }
      ]
    },
    {
      "original_label": "ECOG performance score",
      "standardized_name": "ECOG Performance Status",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status",
      "category": "0",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 106.0,
          "percentage": 61.0,
          "raw_string": "106 61"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 101.0,
          "percentage": 59.0,
          "raw_string": "101 59"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status",
      "category": "1",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 64.0,
          "percentage": 37.0,
          "raw_string": "64 37"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 64.0,
          "percentage": 38.0,
          "raw_string": "64 38"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status",
      "category": "2",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 2"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.0,
          "raw_string": "2 1"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "ECOG Performance Status",
      "category": "Missing",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG Performance Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 0"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 2"
        }
      ]
    },
    {
      "original_label": "Disease-free interval, years",
      "standardized_name": "Disease-Free Interval",
      "unit": "years",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "De novo",
      "standardized_name": "Disease-Free Interval Category",
      "category": "De novo",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-Free Interval",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 74.0,
          "percentage": 43.0,
          "raw_string": "74 43"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 81.0,
          "percentage": 48.0,
          "raw_string": "81 48"
        }
      ]
    },
    {
      "original_label": "< 1",
      "standardized_name": "Disease-Free Interval Category",
      "unit": "years",
      "category": "<1",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-Free Interval",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 6.0,
          "raw_string": "11 6"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 2.0,
          "percentage": 1.0,
          "raw_string": "2 1"
        }
      ]
    },
    {
      "original_label": "1 to < 2",
      "standardized_name": "Disease-Free Interval Category",
      "unit": "years",
      "category": "1 to <2",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-Free Interval",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 16.0,
          "percentage": 9.0,
          "raw_string": "16 9"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 11.0,
          "percentage": 6.0,
          "raw_string": "11 6"
        }
      ]
    },
    {
      "original_label": "> 2",
      "standardized_name": "Disease-Free Interval Category",
      "unit": "years",
      "category": ">2",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-Free Interval",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 75.0,
          "percentage": 43.0,
          "raw_string": "75 43"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 77.0,
          "percentage": 45.0,
          "raw_string": "77 45"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "Disease-Free Interval Category",
      "category": "Missing",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Disease-Free Interval",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 2"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 2"
        }
      ]
    },
    {
      "original_label": "No. of metastatic sites",
      "standardized_name": "Number of Metastatic Sites",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "Number of Metastatic Sites",
      "category": "1",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Metastatic Sites",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 56.0,
          "percentage": 32.0,
          "raw_string": "56 32"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 60.0,
          "percentage": 35.0,
          "raw_string": "60 35"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "Number of Metastatic Sites",
      "category": "2",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Metastatic Sites",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 54.0,
          "percentage": 31.0,
          "raw_string": "54 31"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 53.0,
          "percentage": 31.0,
          "raw_string": "53 31"
        }
      ]
    },
    {
      "original_label": "3",
      "standardized_name": "Number of Metastatic Sites",
      "category": "3",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Metastatic Sites",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 41.0,
          "percentage": 24.0,
          "raw_string": "41 24"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 16.0,
          "raw_string": "28 16"
        }
      ]
    },
    {
      "original_label": "> 3",
      "standardized_name": "Number of Metastatic Sites",
      "category": ">3",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Metastatic Sites",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 14.0,
          "percentage": 8.0,
          "raw_string": "14 8"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 5.0,
          "raw_string": "9 5"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "Number of Metastatic Sites",
      "category": "Missing",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Number of Metastatic Sites",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 2.0,
          "raw_string": "4 2"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 2"
        }
      ]
    },
    {
      "original_label": "Location of metastatic site",
      "standardized_name": "Location of Metastatic Site",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Bone only",
      "standardized_name": "Location of Metastatic Site",
      "category": "Bone only",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Location of Metastatic Site",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 41.0,
          "percentage": 24.0,
          "raw_string": "41 24"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 41.0,
          "percentage": 24.0,
          "raw_string": "41 24"
        }
      ]
    },
    {
      "original_label": "Visceral",
      "standardized_name": "Location of Metastatic Site",
      "category": "Visceral",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Location of Metastatic Site",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 41.0,
          "percentage": 24.0,
          "raw_string": "41 24"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 41.0,
          "percentage": 24.0,
          "raw_string": "41 24"
        }
      ]
    },
    {
      "original_label": "Bone and visceral",
      "standardized_name": "Location of Metastatic Site",
      "category": "Bone and visceral",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Location of Metastatic Site",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 88.0,
          "percentage": 51.0,
          "raw_string": "88 51"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 83.0,
          "percentage": 49.0,
          "raw_string": "83 49"
        }
      ]
    },
    {
      "original_label": "Tumor characteristics",
      "standardized_name": "Tumor characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "ER status",
      "standardized_name": "Estrogen Receptor Status",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "Estrogen Receptor Status",
      "category": "Positive",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Estrogen Receptor Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 170.0,
          "percentage": 98.0,
          "raw_string": "170 98"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 166.0,
          "percentage": 98.0,
          "raw_string": "166 98"
        }
      ]
    },
    {
      "original_label": "Negative",
      "standardized_name": "Estrogen Receptor Status",
      "category": "Negative",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Estrogen Receptor Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0 0"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 1.0,
          "raw_string": "1 1"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "Estrogen Receptor Status",
      "category": "Missing",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Estrogen Receptor Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 2"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 2"
        }
      ]
    },
    {
      "original_label": "PgR status",
      "standardized_name": "Progesterone Receptor Status",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "Progesterone Receptor Status",
      "category": "Positive",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Progesterone Receptor Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 129.0,
          "percentage": 75.0,
          "raw_string": "129 75"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 133.0,
          "percentage": 78.0,
          "raw_string": "133 78"
        }
      ]
    },
    {
      "original_label": "Negative",
      "standardized_name": "Progesterone Receptor Status",
      "category": "Negative",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Progesterone Receptor Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 41.0,
          "percentage": 24.0,
          "raw_string": "41 24"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 31.0,
          "percentage": 18.0,
          "raw_string": "31 18"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "Progesterone Receptor Status",
      "category": "Missing",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Progesterone Receptor Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 2"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 6.0,
          "percentage": 3.0,
          "raw_string": "6 3"
        }
      ]
    },
    {
      "original_label": "HER2 status",
      "standardized_name": "HER2 Status",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Negative",
      "standardized_name": "HER2 Status",
      "category": "Negative",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "HER2 Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 159.0,
          "percentage": 92.0,
          "raw_string": "159 92"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 152.0,
          "percentage": 89.0,
          "raw_string": "152 89"
        }
      ]
    },
    {
      "original_label": "Positive",
      "standardized_name": "HER2 Status",
      "category": "Positive",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "HER2 Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 5.0,
          "raw_string": "9 5"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 13.0,
          "percentage": 8.0,
          "raw_string": "13 8"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "HER2 Status",
      "category": "Missing",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "HER2 Status",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.0,
          "raw_string": "5 3"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 5.0,
          "percentage": 3.0,
          "raw_string": "5 3"
        }
      ]
    },
    {
      "original_label": "Prior endocrine therapy",
      "standardized_name": "Prior Endocrine Therapy",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "header",
          "raw_string": ""
        },
        {
          "group_name": "Letrozole",
          "data_type": "header",
          "raw_string": ""
        }
      ]
    },
    {
      "original_label": "Any",
      "standardized_name": "Prior Endocrine Therapy",
      "category": "Any",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Endocrine Therapy",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 82.0,
          "percentage": 47.0,
          "raw_string": "82 47"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 83.0,
          "percentage": 49.0,
          "raw_string": "83 49"
        }
      ]
    },
    {
      "original_label": "Tamoxifen",
      "standardized_name": "Prior Endocrine Therapy",
      "category": "Tamoxifen",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Endocrine Therapy",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 35.0,
          "raw_string": "61 35"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 36.0,
          "raw_string": "61 36"
        }
      ]
    },
    {
      "original_label": "Aromatase inhibitor",
      "standardized_name": "Prior Endocrine Therapy",
      "category": "Aromatase inhibitor",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Prior Endocrine Therapy",
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 36.0,
          "percentage": 21.0,
          "raw_string": "36 21"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 43.0,
          "percentage": 25.0,
          "raw_string": "43 25"
        }
      ]
    },
    {
      "original_label": "Prior chemotherapy",
      "standardized_name": "Prior Chemotherapy",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Letrozole + Bevacizumab",
          "data_type": "categorical_count_percentage",
          "count": 72.0,
          "percentage": 42.0,
          "raw_string": "72 42"
        },
        {
          "group_name": "Letrozole",
          "data_type": "categorical_count_percentage",
          "count": 65.0,
          "percentage": 38.0,
          "raw_string": "65 38"
        }
      ]
    }
  ]
}
